Vantage Data Points

China's PD(L)-1 players

After Celgene’s return of tislelizumab rights Beigene will be looking for a new ex-China partner. The volume of work Beigene and others are already doing in China suggests the threat to US players of multiple low-cost, Asia-developed drugs.

Image can be enlarged by opening in new tab on Chrome or other browsers.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.